Risk-Based Monitoring (RBM) Is No Longer a Clinical-Only Function
Under EU MDR and FDA guidance, ongoing real-world performance and safety monitoring is increasingly required even after market release. Risk-based monitoring has become a core component of life cycle management and post-market clinical follow-up, and the infrastructure most teams built for periodic site visits is not designed to manage what modern hybrid and decentralized trials demand.
This executive brief examines how continuous data streams, AI-enabled oversight, and in silico modeling are transforming the RBM landscape and what MedTech clinical leaders need to address now.
What This Brief Covers
- How connected devices and remote sensors have inverted the traditional data paradigm¹
- Where AI and machine learning add scalable oversight for processing continuous data streams, and where human validation prevents false positives²
- How synthetic data modeling, data filtering, and in silico methods help sponsors stress-test monitoring frameworks before deployment³
- The regulatory and ethical requirements governing continuous data collection under FDA guidance and EU MDR¹
- Four organizational realities every clinical operations team needs to address to modernize RBM
Who This Is For
Clinical affairs leaders, VP-level clinical operations executives, and regulatory strategists responsible for study oversight design and post-market clinical strategy in MedTech.
References
- U.S. Food & Drug Administration. (2024). Digital Health Technologies for Remote Data Acquisition in Clinical Investigations.
- Applied Clinical Trials. (2025). Modernizing Clinical Oversight: The Shift to Adaptive Monitoring.
- Journal of Clinical Innovation. (2025). The Role of In Silico Modeling in Modern Trial Design.
Get Your Copy Now
Fields marked with * are required.
